

[REDACTED]













At Baseline, the proportion of patients with results that were interpreted by the cardiologist as abnormal ranged from 28.6% (in both the FDC + formoterol and the formoterol + formoterol treatment groups), to 64.3% (in the FDC + placebo treatment group). The FDC + placebo treatment group showed a decrease in the number of patients with abnormal Holter interpretations at Week 5. The numbers remained the same in the FDC + formoterol treatment group, and increased in the formoterol + formoterol treatment group. The FDC + placebo treatment group exhibited the largest change, from a Baseline of 64.3% to 35.7% at Week 5.

The most common abnormal finding across all treatment groups was frequent VPCs. The formoterol + formoterol treatment group showed a higher proportion of patients with this finding compared with the other two treatment groups. At Baseline, the FDC + placebo treatment group had the highest proportion of patients with this finding: 35.7%, compared with 14.3% and 28.6% in the FDC + formoterol, and formoterol + formoterol treatment groups, respectively. At Week 5, the formoterol + formoterol treatment group had the highest proportion of patients with this finding: 42.9%, compared with 28.6% and 21.4% in the FDC + placebo and the FDC + formoterol treatment groups, respectively.

**CONCLUSIONS:**

[REDACTED]

**DATE OF REPORT:**

05 November 2009